Cantargia reports Phase I/IIa data for cancer candidate CAN04

In October, Cantargia AB (SSE:CANTA) reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04 led to no serious adverse events. The first part of the open-label, European trial is evaluating escalating doses of CAN04 in 15-20 patients with non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer or triple-negative breast cancer (TNBC), and the second part will evaluate CAN04 as monotherapy in about 20 patients with NSCLC or pancreatic cancer and in combination with standard of care (SOC) in 25-30 patients. The trial is evaluating safety, pharmacokinetics and tumor response...